Novel x-conotoxin peptides (-1)
AssigneeXenome Limited
InventorsRichard Lewis, Paul Alewood, Dianne Alewood, Elka Palant
Life of this patent
Estimating the term…
Loading patent…
AssigneeXenome Limited
InventorsRichard Lewis, Paul Alewood, Dianne Alewood, Elka Palant
Estimating the term…
An isolated, synthetic or recombinant χ-conotoxin peptide comprising the following sequence of amino acids: Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof. The invention also relates to pharmaceutical compositions comprising those peptides and the use of these peptides in the prophylaxis or treatment of conditions, such as but not limited to, pain, inflammation, incontinence, cardiovascular conditions and mood disorders.
An isolated, synthetic or recombinant %-conotoxin peptide comprising the following sequence of amino acids:
A method for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases or mood disorders or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation comprising administering to a mammal an effective amount of an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit neuronal noradrenaline transporter, wherein said χ-conotoxin peptide comprises the following sequence of amino acids:
Dependencies are inferred from the claim text.